Anagrelide Mevon: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Anagrelide

Indications/Uses

Reduction of elevated platelet counts in patients w/ essential thrombocythaemia who are intolerant to their existing therapy or for whom other therapies are not considered appropriate.

Dosage/Direction for Use

Initially 1 mg/day in 2 divided doses maintained for at least 1 wk. May be titrated after 1 wk, must not exceed 0.5 mg/day in any 1 wk. Max single dose: 2.5 mg.

Administration

May be taken with or without food: Swallow whole, do not crush or dilute contents in liqd.

Contraindications

Hypersensitivity. Moderate or severe hepatic & renal (CrCl <50 mL/min) impairment.

MIMS Class

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

ATC Classification

L01XX35 - anagrelide ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Anagrelide Mevon hard cap 0.5 mg

Packing/Price

1's

Anagrelide Mevon

anagrelide

Manufacturer:

Titan Laboratories